Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

29 August 2025 (09:15 - 10:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Michele D'Alto

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)

4 More presentations in this session

Presentation thumbnail

A real-world study on selexipag for pulmonary arterial hypertension: a single-center retrospective study

Doctor R. Asano (Suita, JP)

Abstract Slides Video

Presentation thumbnail

Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study

Associate Professor H. Tokgoz (Istanbul, TR)

Abstract Slides Video

Presentation thumbnail

Efficacy and safety of selexipag based triple combination targeted drug therapy in chinese patients with pulmonary arterial hypertension

Doctor X. Cui (Jinan, CN)

Abstract Slides Video

Presentation thumbnail

Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study

Doctor T. Kam (Shatin, HK)

Abstract Slides Video

Access the full session

Session thumbnail

Pulmonary arterial hypertension therapy

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET

You may be interested in

Congress Session

Phenotyping and risk stratification in pulmonary arterial hypertension

Congress Presentation

Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study

Congress Session

Paradigm change in pulmonary hypertension: from bench to bedside

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources